Literature DB >> 26874348

Higher Adalimumab Drug Levels Are Associated with Mucosal Healing in Patients with Crohn's Disease.

Konstantinos Papamichael1, Adam S Cheifetz2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26874348      PMCID： PMC4957461          DOI： 10.1093/ecco-jcc/jjw041

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN： 1873-9946            Impact factor:   9.071


× No keyword cloud information.
  20 in total

1.  The role of mucosal healing in the treatment of patients with inflammatory bowel disease.

Authors:  Byron P Vaughn; Sveta Shah; Adam S Cheifetz
Journal:  Curr Treat Options Gastroenterol       Date:  2014-03

2.  It Is Time to Treat to Trough: Staying Ahead of the Curve in Biologic Testing.

Authors:  Byron P Vaughn; Adam S Cheifetz
Journal:  Clin Gastroenterol Hepatol       Date:  2015-04-08       Impact factor: 11.382

3.  Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment.

Authors:  Johannan F Brandse; Laura M C Vos; Jeroen Jansen; Toos Schakel; Cyriel I J Ponsioen; Gijs R van den Brink; Geert R D'Haens; Mark Löwenberg
Journal:  J Crohns Colitis       Date:  2015-06-26       Impact factor: 9.071

4.  High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy.

Authors:  Steven A Hendler; Benjamin L Cohen; Jean-Frédéric Colombel; Bruce E Sands; Lloyd Mayer; Shradha Agarwal
Journal:  J Crohns Colitis       Date:  2014-12-24       Impact factor: 9.071

5.  The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study.

Authors:  Andres J Yarur; Anjali Jain; Daniel A Sussman; Jamie S Barkin; Maria A Quintero; Fred Princen; Richard Kirkland; Amar R Deshpande; Sharat Singh; Maria T Abreu
Journal:  Gut       Date:  2015-02-10       Impact factor: 23.059

6.  Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis.

Authors:  Johannan F Brandse; Gijs R van den Brink; Manon E Wildenberg; Desiree van der Kleij; Theo Rispens; Jeroen M Jansen; Ron A Mathôt; Cyriel Y Ponsioen; Mark Löwenberg; Geert R A M D'Haens
Journal:  Gastroenterology       Date:  2015-04-25       Impact factor: 22.682

7.  Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.

Authors:  Xavier Roblin; Hubert Marotte; Melanie Rinaudo; Emilie Del Tedesco; Amelie Moreau; Jean Marc Phelip; Christian Genin; Laurent Peyrin-Biroulet; Stephane Paul
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-23       Impact factor: 11.382

Review 8.  Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel Disease.

Authors:  Clare Moore; Gillian Corbett; Alan C Moss
Journal:  J Crohns Colitis       Date:  2016-01-13       Impact factor: 9.071

9.  Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.

Authors:  Bella Ungar; Idan Levy; Yarden Yavne; Miri Yavzori; Orit Picard; Ella Fudim; Ronen Loebstein; Yehuda Chowers; Rami Eliakim; Uri Kopylov; Shomron Ben-Horin
Journal:  Clin Gastroenterol Hepatol       Date:  2015-10-29       Impact factor: 11.382

Review 10.  Are Anti-Tumor Necrosis Factor Trough Levels Predictive of Mucosal Healing in Patients With Inflammatory Bowel Disease?: A Systematic Review and Meta-Analysis.

Authors:  Edward L Barnes; Jessica R Allegretti
Journal:  J Clin Gastroenterol       Date:  2016-10       Impact factor: 3.062
View more
  3 in total

Review 1.  Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.

Authors:  Nicholas Carman; David R Mack; Eric I Benchimol
Journal:  Curr Gastroenterol Rep       Date:  2018-04-05

2.  Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease.

Authors:  Anna Juncadella; Konstantinos Papamichael; Byron P Vaughn; Adam S Cheifetz
Journal:  Dig Dis Sci       Date:  2018-07-13       Impact factor: 3.199

3.  Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn's Disease.

Authors:  Konstantinos Papamichael; Shana Rakowsky; Claudio Rivera; Adam S Cheifetz; Mark T Osterman
Journal:  Inflamm Bowel Dis       Date:  2018-09-15       Impact factor: 5.325
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.